Feira Nishee
Autoimmune diseases, such as Rheumatoid Arthritis (RA), Crohn’s
disease, psoriatic arthritis, and Inflammatory Bowel Disease (IBD), represent
a diverse group of disorders in which the immune system mistakenly attacks
the body’s tissues, leading to chronic inflammation, tissue damage, and a
reduction in quality of life. Over the past few decades, biologic therapies, which
specifically target immune system components involved in inflammation,
have revolutionized the management of autoimmune diseases. Among
these biologics, Infliximab stands out as one of the first Tumor Necrosis
Factor-Alpha (TNF-α) inhibitors developed to treat inflammatory conditions.
Share this article
